Pharmaceutical industry diseases

The separation of enantiomers is a very important topic to the pharmaceutical industry. It is well recognized that the biological activities and bioavailabilities of enantiomers often differ [1]. To further complicate matters, the pharmacokinetic profile of the racemate is often not just the sum of the profiles of the individual enantiomers. In many cases, one enantiomer has the desired pharmacological activity, whereas the other enantiomer may be responsible for undesirable side-effects. What often gets lost however is the fact that, in some cases, one enantiomer may be inert and, in many cases, both enantiomers may have therapeutic value, though not for the same disease state. It is also possible for one enantiomer to mediate the harmful effects of the other enantiomer. For instance, in the case of indacrinone, one enantiomer is a diuretic but causes uric acid retention, whereas the other enantiomer causes uric acid elimination. Thus, administration of a mixture of enantiomers, although not necessarily racemic, may have therapeutic value. 

The foundation for the more rational approach to drug discovery that is practised today comes from basic research into disease processes and medical conditions. Much of this research is carried out in universities and other research institutions, with funding coming from both government and pharmaceutical industry sponsors. 

In the pharmaceutical industry, GA is used in pharmaceutical preparations and as a carrier of drugs since it is considered a physiologically harmless substance. Additionally, recent studies have highlighted GA antioxidant properties (Trommer Neubert, 2005 Ali Al Moundhri, 2006 Hinson et al., 2004), its role in the metabolism of lipids (Tiss et al., 2001, Evans et al., 1992), its positive results when being used in treatments for several degenerative diseases such as kidney failure (Matsumoto et al., 2006 Bliss et al., 1996 Ali et al., 2008), cardiovascular (Glover et al., 2009) and gastrointestinal (Wapnir et al., 2008 Rehman et al, 2003). 

C03-0117. Heart disease causes 37% of the deaths in the United States. However, the death rate from heart disease has dropped significantly in recent years, partly because of the development of new drugs for heart therapy by chemists working in the pharmaceutical industry. One of these drugs is verapamil, used for the treatment of arrhythmia, angina, and h q)ertension. A tablet contains 120.0 mg of verapamil. Determine the following quantities (a) the molar mass of verapamil (b) the number of moles of verapamil in one tablet and (c) the number of nitrogen atoms in one tablet. 

One of the first and most useful medicinal chemicals is aspirin (CgHgO ), also known as acetylsalicylic acid. This painkiller was first trademarked and manufactured in 1899, but a precursor to the drug had been extracted from the bark of willow trees by Hippocrates as early as the 5th century b.c. The pharmaceutical industry has since developed an array of products to alleviate aches and pains, yet aspirin is still prominent on the shelves of drugstores. In pharmacies that dispense prescription drugs, an even wider array of chemicals is sold to help those with diseases ranging from high blood pressure to cancer. 

With this evidence of disease relevance, discovering and developing high-quality chemical probes [23] of PMTs has been gaining momentum in both the academic research community and the pharmaceutical industry. Progress in this area is keenly awaited. 

The first stages of development of the modern pharmaceutical industry can be traced back to the turn of the twentieth century. At that time (apart from folk cures), the medical community had at their disposal only four drugs that were effective in treating specific diseases ... 

---